Location: Singapore
Total raised: $8M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.07.2026 | Series A | $8M | - |
Mentions in press and media 6
| Date | Title | Description |
| 30.07.2026 | Tikva Allocell Secures $8 Million to Transform Solid Tumor Therapy | Tikva Allocell secured substantial funding. The biotechnology firm, based in Singapore, announced an $8 million Series A financing round. Kantharos Capital led this crucial investment. This capital injection significantly accelerates a pion... |
| 27.07.2026 | Singapore’s Tikva Allocell raises $8 M Series A funding from Kantharos Capital | The biotechnology business Tikva Allocell Pte. Ltd. (Tikva), situated in Singapore, said on Wednesday that it has closed a $8 million Series A funding led by Kantharos Capital. According to a statement from Tikva, the proceeds will support ... |
| 24.07.2026 | Tikva Allocell Closes $8 Million Series A Financing For EBV-Specific T-Cell Therapy | Tikva Allocell, a biotechnology company developing engineered, allogeneic cell therapies for solid tumors, announced the closing of an $8 million Series A financing led by Kantharos Capital. Proceeds will fund activities required to enable ... |
| 22.07.2026 | Tikva Allocell Closes $8 Million Series A Financing to Advance Engineered EBV-Specific T-Cell Therapy for Solid Tumors | Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targeting B7-H3-positive solid tumors SINGAPORE, July 22, 2026 /PRNewswire/ -- Tikva Allo... |
| 22.07.2026 | Venture capital & startup funding roundup, July 22, 2026: Andreessen Horowitz, Redpoint Ventures, Sequoia Capital, Insight Partners & more | If there was one clear signal in today’s funding landscape, it was that venture investors are no longer paying simply for “AI exposure.” They are paying for control points: endpoint security, military cyber operations, healthcare billing in... |
| - | Tikva Allocell | “tikva-allocell” |